Postmarket Cybersecurity for Medical Devices: The FDA Roadmap

[DIRECT ANSWER] FDA postmarket cybersecurity guidance requires cleared device manufacturers to maintain an active vulnerability management program across the device's commercial life. Core obligations under Section 524B and the FDA's Postmarket Management of Cybersecurity in Medical Devices guidance include: continuous SBOM monitoring, a published coordinated vulnerability disclosure policy, validated patch management with documented rationale, and incident reporting under 21 CFR Part 806 when corrections could prevent death or serious injury.

FDA clearance is the beginning of your cybersecurity obligations, not the finish line. Postmarket cybersecurity for medical devices is an active, continuous requirement that most manufacturers underestimate until a problem forces their hand. Most invest significant resources building premarket documentation, then treat ongoing security management as something to address only when something breaks. That gap is exactly where regulatory risk accumulates, and where patient safety gets quietly compromised.

This guide covers what the FDA actually requires from cleared device makers on an ongoing basis: the statutory framework behind postmarket cybersecurity obligations, how a functioning vulnerability management program works, what patch validation and incident reporting look like in practice, and what documentation you need on file to demonstrate diligence. If your team doesn’t have the internal capacity to run this program reliably, Blue Goat Cyber specializes exclusively in building and managing these programs for cleared device makers so nothing falls through the cracks.

Key Takeaways

• FDA postmarket cybersecurity guidance requires cleared device makers to maintain active vulnerability monitoring, patch validation, and coordinated disclosure - not just document intent.
• The Postmarket Management of Cybersecurity in Medical Devices guidance (2016) and Section 524B (2023) form the two-layer statutory basis for these obligations.
• SBOM currency is the foundation of every other postmarket obligation - you cannot monitor what you haven’t inventoried.
• Reporting thresholds under 21 CFR Part 806 are specific: corrections expected to prevent death or serious injury require reporting within 10 working days. Document your rationale for every determination that falls below that threshold.
• The gap between a cleared device and a defensible postmarket program is real and measurable - the 30/60/90-day checklist in this post gives you the build sequence.

What the FDA Postmarket Cybersecurity Guidance Actually Requires

Postmarket Management of Cybersecurity in Medical Devices: The 2016 Guidance and Section 524B

The FDA finalized its Postmarket Management of Cybersecurity in Medical Devices guidance on December 27, 2016. That document established a risk-based framework for managing cybersecurity vulnerabilities across the full device lifecycle, covering everything from monitoring and assessment through mitigation and disclosure. It wasn’t optional in practice: manufacturers who ignored it still needed to demonstrate device safety and effectiveness under existing law. The full FDA postmarket cybersecurity guidance is also available as an official downloadable PDF for reference: FDA postmarket cybersecurity guidance PDF.

Section 524B of the FD&C Act, which took effect March 29, 2023, moved the needle further. Manufacturers of “cyber devices” must now include a postmarket cybersecurity plan in their premarket submission, covering how they will monitor, identify, and address vulnerabilities after clearance. The obligation doesn’t expire once the device ships. It’s a continuous requirement tied to the device’s commercial life, and the FDA’s February 2026 guidance updates reinforce that posture with enhanced SBOM requirements and stricter lifecycle documentation expectations. For a targeted breakdown of how recent regulatory updates affect device makers, see FDA Cybersecurity Requirements for Medical Devices (2026 Update).

Which devices fall under these obligations

The framework applies to any device that uses software, including programmable logic, mobile medical apps, and software regulated as a device. The vast majority of connected devices on the market qualify as “cyber devices” under the statute’s definition. Ignoring these obligations isn’t a gray area: the FDA explicitly ties cybersecurity to device safety and effectiveness, which means a gap in your postmarket program is a gap in your safety case.

Building a vulnerability monitoring program that holds up

Where to monitor and how to filter signal from noise

A monitoring program that doesn’t scale is one that gets abandoned. Manufacturers need to pull from specific, authoritative sources continuously: the National Vulnerability Database, ICS-CERT medical advisories, vendor security bulletins, and third-party component trackers. Without a structured intake mechanism, the volume of incoming advisories becomes unmanageable fast.

The key is screening incoming data against the device’s actual software components, which is exactly what your Software Bill of Materials makes possible. A current, accurate SBOM for your device lets you eliminate irrelevant vulnerability reports immediately and focus engineering attention on components that are actually present in your build. Without a current SBOM, your team faces an impossible choice: drown in noise or miss something critical. For a deeper look at lifecycle practices that include SBOM management and related monitoring, see Medical Device Cybersecurity: A Complete Lifecycle Guide.

Scoring risk with clinical impact in mind

The FDA recommends using the Common Vulnerability Scoring System as a baseline, but manufacturers cannot stop there. CVSS scores reflect technical severity in a generic context. They don’t account for what happens when that vulnerability exists in a cardiac monitor or an infusion pump in a clinical setting.

The FDA’s postmarket guidance recommends a two-factor assessment: exploitability of the vulnerability combined with the severity of patient harm if that vulnerability were exploited. A moderate CVSS score on a component that governs essential clinical performance carries a fundamentally different risk profile than the same score on a logging module. Clinical impact is the determining factor, and your risk documentation needs to reflect that reasoning explicitly.

Postmarket patch management: validation, timing, and deployment

The validated patch testing process

Patches for cleared medical devices aren’t hotfixes. The FDA expects software updates to go through a design verification and validation process that includes regression testing against essential clinical performance, documentation of the testing rationale, and evidence that the update doesn’t introduce new risk. This is a meaningful departure from how most software teams handle security patches.

One practical structure that works: a dedicated software-sustaining engineering group that handles third-party patch validation separately from new product development. This separation lets the team respond quickly to incoming advisories without disrupting active development cycles. It also creates a clear audit trail showing that patch work follows a defined, repeatable process rather than ad hoc remediation.

When you must report versus when you can act quietly

Under 21 CFR Part 806, manufacturers must report corrections to the FDA within 10 working days when a vulnerability correction could reasonably be expected to prevent death or serious injury. That’s the threshold that triggers mandatory reporting, and it’s specific. Proactive cybersecurity improvements that don’t meet that threshold do not require FDA reporting under the postmarket guidance, which gives manufacturers meaningful room to patch routinely without triggering a formal submission.

What you do need is documented rationale for that determination. Every time your team assesses a vulnerability and concludes that a correction falls below the reporting threshold, that conclusion needs to be recorded in the risk management file with the reasoning that supports it. That record is what protects you during an inspection or audit.

Coordinated vulnerability disclosure and FDA incident reporting

CVD policy structure and realistic timelines

Every cleared device manufacturer needs a published coordinated vulnerability disclosure policy. The core components are straightforward: a secure intake channel (a dedicated security email address or web form), a commitment to acknowledge reports within a defined timeframe, severity-based response timelines, and a process for coordinating with other affected vendors when a vulnerability spans multiple products.

Standard timelines run 60 to 90 days for typical vulnerabilities, with expedited response when active exploitation is observed. CERT/CC and FIRST set the norms here, and aligning your policy with their frameworks signals to researchers that you take disclosure seriously. For multi-party coordination specifics and accepted procedural norms, consult the multiparty coordinated vulnerability disclosure guidelines.

Multi-party coordination is the hardest part operationally. Establishing those relationships upstream with component vendors before a vulnerability surfaces is far easier than trying to coordinate during a live incident. That groundwork is worth building now.

Notifying customers, healthcare facilities, and the FDA

When a vulnerability is confirmed and a patch is available, the notification sequence matters. Internal triage comes first, followed by healthcare facility notification with clear remediation instructions, then patient or provider notification where the clinical risk warrants it. FDA Medical Device Reporting under 21 CFR Part 803 applies when the cybersecurity risk meets the threshold for serious injury or death.

The content of notifications carries real weight. Vague advisories that don’t identify affected product versions, don’t include a clinical risk assessment, and don’t provide specific remediation steps aren’t acceptable. Specificity is expected, and healthcare facilities need actionable information to protect patients. Notifications that bury the important details in boilerplate undermine the entire purpose of the disclosure process.

The documentation your compliance program needs on file

Maintaining and updating your SBOM

The FDA’s updated guidance requires manufacturers to keep their SBOM current across the device’s commercial life. That means tracking all commercial, open-source, and off-the-shelf components with accurate version information, updated whenever the software changes. An SBOM that reflects a build from two years ago is functionally useless for vulnerability monitoring because you can’t match NVD advisories against components you haven’t tracked accurately.

Traceability matters here too. The FDA expects a clear link between components in the SBOM and known vulnerabilities identified through monitoring. The cadence for SBOM review should tie directly to software updates and any discovery of new relevant vulnerabilities. For teams using CI/CD pipelines, automating SBOM generation at each release is the most reliable way to keep this current without adding manual overhead.

Risk management records that demonstrate ongoing diligence

A postmarket surveillance security program is only as defensible as its records. The FDA expects documentation of each vulnerability assessment, including the input data, the scoring rationale, the clinical impact determination, and the resulting decision. Patch validation test reports, CVD communications, MDR submissions, and updates to the cybersecurity risk management plan all belong in this file.

These records serve a purpose beyond audit preparation. They form the chain of evidence that proves your program is active and functioning, not just documented on paper. An inspector who can trace a vulnerability from initial discovery through assessment, remediation, and notification is looking at a program that works. An inspector who finds gaps in that chain is looking at a liability.

When to Use a Managed Postmarket Cybersecurity Program

Why the ongoing burden catches manufacturers off guard

Most device teams staff for the sprint to clearance. The premarket phase has a defined endpoint, and headcount decisions reflect that. Postmarket cybersecurity risk management has no endpoint: new vulnerabilities appear daily, SBOMs need updating after every software release, CVD responses require fast coordination, and documentation must stay current across the device’s entire commercial life. Teams without a dedicated product security function find this is where programs quietly stop working.

When a specialized partner changes the equation

Some manufacturers choose to work with specialized firms that build and manage postmarket compliance programs on their behalf. Medical Device Cybersecurity Postmarket Management Requirements (2026), Blue Goat Cyber is one resource that describes the mechanics a managed program should cover. The firm focuses exclusively on medical device cybersecurity, offering continuous postmarket compliance programs that cover vulnerability monitoring, patch management coordination, SBOM maintenance, and CVD policy implementation, along with all required regulatory documentation.

For device makers without the internal bandwidth to run this program reliably, that kind of specialized support keeps compliance active without pulling engineering resources away from product development. The alternative is a program that exists on paper but breaks down in practice, a risk that compounds over time as your device fleet ages and new vulnerabilities accumulate.

---

If you need a managed postmarket cybersecurity program built to FDA's current guidance expectations, Blue Goat Cyber handles the full program - SBOM monitoring, vulnerability assessment, patch coordination, CVD policy, and all required documentation. If FDA ever raises cybersecurity issues with a device we manage, we resolve them at no additional cost.

→ Book a free postmarket strategy call

---

Your next step

Postmarket cybersecurity medical device obligations are active and ongoing, tied directly to the FDA’s definition of device safety. Manufacturers who build a functioning program covering vulnerability monitoring, validated patch management, coordinated disclosure, and rigorous documentation protect both patients and their regulatory standing simultaneously.

The FDA has made its expectations clear: proactive compliance is required, not optional. The gap between a cleared device and a defensible ongoing program is real, and it needs to be closed deliberately.

30/60/90-Day Postmarket Cybersecurity Implementation Checklist

Use this checklist to build and operationalize your postmarket cybersecurity program in the first 90 days after launch.

First 30 Days: Build the Backbone

• Assign ownership and escalation paths
• Create and test a vulnerability intake channel
• Define triage criteria and severity rules
• Inventory products, versions, and deployment environments

By 60 Days: Operationalize Monitoring and SBOM Use

• Establish SBOM coverage for shipping products and major supported versions
• Set up vulnerability monitoring tied to your SBOM
• Define patch release steps (including verification expectations)
• Create customer advisory templates (clear, actionable, non-alarmist)

By 90 Days: Prove You Can Execute

• Run a tabletop exercise: “New CVE impacts our device - what happens next?”
• Measure response time from intake → triage → decision → guidance
• Fix bottlenecks (ownership, testing, approvals, customer communications)
• Start recurring reviews with basic metrics and continuous improvement

Common Postmarket Mistakes to Avoid

• No defined workflow (everything is ad hoc)
• No coordinated vulnerability disclosure path (or an inbox nobody monitors)
• Risk decisions not tied to device context or patient impact
• SBOM created once and never updated
• Patches released without adequate verification and validation
• Customer communications that are vague, late, or overly technical
• No evidence trail (which makes audits and future submissions harder)

Related Articles in This Series

• PATCH Act Only Applies to New Medical Devices, Leaves Legacy Systems a Risk
• Ventilator Recalled for Cybersecurity Risk: Was a Lack of Secure by Design the Cause?
• Securely Updating Medical Devices
• Medical Device OTA Update Vulnerabilities
• What is a Coordinated Vulnerability Disclosure Process?
• IMDRF: Harmonizing Med Device Regulations

Frequently Asked Questions

What does FDA's postmarket cybersecurity guidance actually require from cleared device manufacturers?

The FDA postmarket cybersecurity guidance imposes five continuous obligations: vulnerability monitoring tied to a current SBOM, a published coordinated vulnerability disclosure (CVD) policy, validated patch management with documented rationale, FDA incident reporting under 21 CFR Part 806 when corrections could prevent death or serious injury, and ongoing risk management records. These flow from the 2016 Postmarket Management of Cybersecurity in Medical Devices guidance and Section 524B of the FD&C Act.

When must a manufacturer report a cybersecurity vulnerability to the FDA?

Under 21 CFR Part 806, manufacturers must report a correction within 10 working days when that correction could reasonably be expected to prevent death or serious injury. Proactive cybersecurity improvements below that threshold do not require FDA reporting - but your rationale for that determination must be documented in the risk management file. That documented reasoning is what protects the determination during an inspection.

How often does the SBOM need to be updated after clearance?

The SBOM must be updated with every software change - new components, version bumps, removed dependencies. For teams using CI/CD pipelines, automate SBOM generation at each release. The FDA expects the SBOM to reflect the current shipping build, not the submission-time snapshot. A stale SBOM makes vulnerability monitoring functionally impossible because incoming advisories cannot be reliably matched against components actually present in your device.

What is a coordinated vulnerability disclosure policy and does our device need one?

A CVD policy defines how you receive, acknowledge, assess, and respond to vulnerability reports from external researchers. If your device qualifies as a cyber device under Section 524B, this is an FDA expectation. Core elements: a secure intake channel, a defined acknowledgment timeframe, severity-based response windows (typically 60–90 days), and a multi-vendor coordination process for vulnerabilities that span multiple products or components.

What happens if we don't have a functioning postmarket cybersecurity program and FDA asks about it?

FDA ties cybersecurity directly to device safety and effectiveness, so a gap in your postmarket program is a gap in your safety case. During inspections, FDA can request vulnerability monitoring records, SBOM update history, patch validation reports, and CVD communications. Programs that exist on paper but not in practice are a documented liability. Blue Goat Cyber resolves all cybersecurity deficiencies at no additional cost for devices under our management.

---

About the Author

Christian Espinosa | Founder & CEO, Blue Goat Cyber | CISSP

Christian has built and managed postmarket cybersecurity programs for device manufacturers across 250+ FDA submissions. He founded Blue Goat Cyber to solve a problem he experienced personally: most MedTech teams clear their devices and then discover postmarket obligations with no infrastructure in place to meet them.

---

Audit Your Postmarket Program

If FDA raises cybersecurity deficiencies on a device we manage, we resolve them at no additional cost. Book a free postmarket strategy call to audit your current program and identify what needs to be closed.

Book a free postmarket strategy call

30 minutes · No cost · No commitment

The Med Device Cyber Podcast

Follow Blue Goat Cyber on Social

LinkedinYoutubeInstagramTwitter